Austin, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ankylosing Spondylitis Market Size & Growth Analysis
According to SNS Insider, the Ankylosing Spondylitis Market was valued at USD 5.77 billion in 2023 and is projected to reach USD 11.15 billion by 2032, expanding at a CAGR of 7.59% from 2024–2032. The U.S. market alone accounted for USD 2.67 billion in 2023 and is expected to nearly double, reaching USD 5.05 billion by 2032 at a CAGR of 7.33%.
This growth is fueled by the rising global prevalence of ankylosing spondylitis (AS), increasing patient awareness, and breakthroughs in biologic and biosimilar therapies that are redefining treatment protocols.
Get Free Sample Report of the Ankylosing Spondylitis Market: https://www.snsinsider.com/sample-request/6815
Market Overview
Ankylosing spondylitis, a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is increasingly being diagnosed due to improved imaging and awareness campaigns. In the U.S., robust insurance coverage for biologics, along with fast-tracked FDA approvals of novel monoclonal antibodies, is accelerating patient adoption. Globally, the expansion of precision medicine and personalized rheumatology treatment is expected to significantly enhance therapeutic outcomes and long-term disease management.
Major Players Analysis Listed in this Report are:
- AbbVie Inc. (Humira, Rinvoq)
- Pfizer Inc. (Xeljanz, Enbrel)
- Novartis AG (Cosentyx, Voltaren)
- Johnson & Johnson (Janssen Pharmaceuticals) (Simponi, Remicade)
- Eli Lilly and Company (Taltz, Olumiant)
- Amgen Inc. (Enbrel, Otezla)
- Bristol-Myers Squibb Company (Zeposia, Orencia)
- UCB S.A. (Cimzia, Bimzelx)
- Biogen Inc. (Benepali, Imraldi)
- Roche Holding AG (Actemra, MabThera)
- Sanofi S.A. (Kevzara, Aubagio)
- Merck & Co., Inc. (Arcoxia, Remicade - co-marketed)
- Takeda Pharmaceutical Company Limited (Entyvio, Mobic)
- Gilead Sciences, Inc. (Jyseleca, Filgotinib)
- Samsung Bioepis Co., Ltd. (Brenzys, Hadlima)
- Sun Pharmaceutical Industries Ltd. (Omalizumab, Etoricoxib)
- Zydus Lifesciences Ltd. (Adalimumab biosimilar, Etoricoxib)
- Dr. Reddy's Laboratories (Adalimumab biosimilar, Etoricoxib)
- Hetero Drugs Ltd. (Adalimumab biosimilar, Infliximab biosimilar)
- Lupin Limited (Etanercept biosimilar, Indomethacin)
Ankylosing Spondylitis Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | USD 5.77 billion |
| Market Size by 2032 | USD 11.15 billion |
| CAGR | CAGR of 7.59 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2021 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Segment Analysis
By Treatment, the Non-steroidal Anti-inflammatory Drugs Segment Dominated in 2023
The NSAIDs segment led the ankylosing spondylitis market in 2023 with a 48.1% market share, attributed to their use as first-line treatment for pain and inflammation. NSAIDs are cost-effective and available over the counter or in generic forms, and they are effective in relieving symptoms and improving mobility early in the course of the illness. NSAIDs do not necessitate specialized administration, unlike biologics.
In terms of Route of Administration, the Parenteral segment will hold the largest market share.
The ankylosing spondylitis market was led by the parenteral segment in 2023, as biologics and biosimilars are almost exclusively delivered via injection or infusion. These main aspects of therapy are TNF-inhibitors and IL-17 inhibitors, as they can act locally and the therapeutic response is more effective than the mouth alternative medication. Moderate to severe DUAG, a nucleophilic disease, requires parenteral administration for its higher bioavailability and faster therapeutic effect.
Segment of Prescription Drugs Holds Largest Market Share by Type
The prescription drugs segment accounted for the largest ankylosing spondylitis market share in 2023, as they continue to be the treatment of choice for disease control (including various fillings-based biologics, biosimilars, JAK inhibitors, and NSAIDs). In addition, prescription medications are more effective, work faster, and provide long-term relief of symptoms compared to over-the-counter treatments. This trend has been fueled by increased advancements in biologic injectables and novel oral therapies.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/6815
Ankylosing Spondylitis Market Segmentation
By Treatment
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Biologic therapies
- TNF inhibitors
- IL-17 inhibitors
- JAK Inhibitors
- Disease-modifying anti-rheumatic drugs (DMARDs)
- Corticosteroids
By Route of Administration
- Parenteral
- Oral
By Type
- Prescription drugs
- OTC drugs
By Application
- Adults
- Juveniles
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
The Ankylosing Spondylitis Market in North America is Dominated with 56.22% Market Share in 2023; the Asia-Pacific is Predicted to Register the Fastest Growth.
The highest share of the North American ankylosing spondylitis market is due to a high level of healthcare infrastructure, relatively high numbers of patient diagnoses compared with the market size population, and relatively easy access to more expensive biologics and biosimilars. Market growth is also propelled by a sound reimbursement framework, the presence of major pharmaceutical companies, and strong clinical research activity.
Asia-Pacific is expected to exhibit the fastest growth in the ankylosing spondylitis market with 8.10% CAGR over the forecast period due to rising prevalence and increases in healthcare expenditure, and better access to modern therapies. Increased medical insurance coverage and chronic disease management initiatives by the government are facilitating treatment adoption. Furthermore, an increase in the presence of international pharmaceutical companies and an improvement in diagnostic abilities tend to boost the market growth.
Buy the Full Ankylosing Spondylitis Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/6815
Unique Selling Propositions (USPs) of the Report:
Therapy Adoption & Patient Journey Mapping
understand gaps in treatment, pain points of patients, and the behavior of patients in switching to design strategies around patients.
Pricing, Reimbursement & Access Strategy Insight
Offers insights on payor dynamics and cost barriers, providing clarity on market entry and price decisions.
Unmet Needs & Pipeline Differentiation Matrix
Identify innovation opportunities and competitive whitespace to inform R&D and partnership strategy.
Physician Attitude & Behavior
Provides actionable information on prescription patterns and therapy preferences to help refine targeting.
RWE & Treatment Outcomes Insights
Provides validation of long-term drug performance and safety to amp up the position in the market.
Market Access & Distribution Channel Assessment
It helps to assess the most successful distribution paths and obstacles to market entry to maximize product penetration.
Regulatory & Policy Impact Assessment
Predicts policy movements and potential regulatory pathways so you can minimize compliance risks and expedite approvals.
Access Complete Report Details of Ankylosing Spondylitis Market Analysis & Outlook@ https://www.snsinsider.com/reports/ankylosing-spondylitis-market-6815
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
